Evidence map›Paper›PMID 30254401›Full record

ArticleWorld journal of gastroenterology2018

Role of endoscopic therapy in early esophageal cancer.

Sonika Malik, Gautam Sharma, Madhusudhan R Sanaka, Prashanthi N Thota

Open access · hybridAbstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 40 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Current status and application of proton therapy for esophageal cancer.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2021
    Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Sonika MalikDepartment of Internal Medicine, Cleveland Clinic Akron General Medical Center, Akron, OH 44307, United States.
Gautam SharmaDepartment of Anesthesiology, University Hospitals, Cleveland, OH 44106, United States.
Madhusudhan R SanakaDepartment of Gastroenterology, Digestive Disease Surgery Institute, Cleveland Clinic, OH 44195, United States.
Prashanthi N ThotaDepartment of Gastroenterology, Digestive Disease Surgery Institute, Cleveland Clinic, OH 44195, United States. thotap@ccf.org.
Cleveland Clinic · USAkron General Medical Center · US

Funding

Whole Exome Approaches for Esophageal Adenocarcinoma Susceptibility GenesU54CA163060 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI CHAK, AMITABH, GUDA, KISHORE · 2011 to 2022
$14.0M
NCI NIH HHS U54 CA163060
6 · The paper itself

Abstract

Esophageal carcinoma is a highly lethal cancer associated with high morbidity and mortality. Esophageal squamous cell carcinoma and esophageal adenocarcinoma are the two distinct histological types. There has been significant progress in endoscopic diagnosis and treatment of early stages of cancer using resection and ablation techniques, as shown in several trials in the recent past. Earlier detection of esophageal cancer and advances in treatment modalities have lead to improvement in the 5-year survival from 5% to about 20% in the past decade. Endoscopic eradication therapy is the preferred modality of treatment in cancer limited to mucosal layer of the esophagus as there is very low risk of lymph node metastasis, leading to high cure rates, low risk of recurrence and with few adverse effects. The most common adverse events seen are strictures, bleeding and rarely perforation which can be endoscopically managed. In patients with recurrent advanced disease or invasive tumor, esophagectomy with lymph node dissection remains the mainstay of treatment. There is debate on post-endoscopic surveillance with some studies suggesting closer follow up with upper endoscopy every 6 mo for the first 1-2 years and then annually for the 3 years while others recommending the appropriate action only if symptoms or other abnormalities develop. Overall, the field of endoscopic therapy is still evolving and focus should be placed on careful patient selection using a multidisciplinary approach.

Indexed as

AdenocarcinomaEndoscopic Mucosal ResectionEsophageal MucosaEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaEsophagectomyEsophagoscopyHumansNeoplasm StagingPatient SelectionPostoperative ComplicationsSurvival RateTreatment OutcomeArgon plasma coagulationCryotherapyEndoscopic mucosal resectionEndoscopic submucosal dissectionEsophageal cancerPhotodynamic therapyRadiofrequency ablation

Identifiers

PMID30254401
PMCPMC6148428
OpenAlexW2890176003

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.